Overview

Use of Activated Recombinant FVII in Spinal Surgery

Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in the United States of America (USA). The purpose of this clinical research trial is to understand how safe and effective Recombinant Activated FVII is for reducing bleeding and blood transfusions in patients undergoing spinal fusion surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Novo Nordisk A/S